To view the full version of this video, please tell us more about yourself. »
Watch AML experts at the 2025 AAMDSIF Bone Marrow Failure Summit translate and discuss the latest science to advance patient outcomes. This session is moderated by Mikkael Sekeres, MD, MS from the University of Miami.
Session Topics:
HMA + Ven vs. 7+3 vs. liposomal cytarabine/daunorubicin for secondary AML – Uma Borate, MD, Ohio State University
Using MRD to Make AML Treatment Decisions – Chris Hourigan, DM, DPhil, FRCP, Virginia Tech FBRI Cancer Research Center
Transplant Yes or No for Older Adults with AML: What factors make the decision? – Noa Holtzman, MD, University of Miami
The best approach for good-risk AML in Older Adults – Kah Poh Loh, MD, MS, FACCC, FASCO, University of Rochester